Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
SpaceX rocket launches 140 satellites into orbit on Transporter-15, aces landing at sea (video) - 2Effectiveness Uncovered: A Survey of \Smoothing out Your Errands\ Efficiency Application
- 3Figure out How to Get the Most Familiar Drive for Seniors in SUVs
- 4Untamed life Safe-havens All over the Planet Offering Remarkable Creature Experiences
- 5The most effective method to Promoter for Cellular breakdown in the lungs Mindfulness in Your People group
- Optimal Beauty Parlor Medicines for Upgraded Wellbeing and Appearance
- Scientists detect X-ray glow from interstellar comet 3I/ATLAS extending 250,000 miles into space
- Grasping the Course of Evacuation and Extradition in U.S. Migration
- Finding the Universe of Workmanship: Individual Encounters in Imagination
- The Delight of Camper Vans: Choosing the One That Meets Your Requirements
- Top 15 Supportable Design Brands Coming out on top
- Machado ‘presented’ her Nobel Peace Prize medal to Trump
- How will the universe end?
- 5 Chiefs That Changed Our Opinion on Film
